Heparin Alone vs. Heparin-Aspirin Combo in Free Flap Survival

Launched by AGA KHAN UNIVERSITY · Jul 16, 2024

Keywords

ClinConnect Summary

This clinical trial is studying the effectiveness of two different treatments—heparin alone and a combination of heparin and aspirin—in helping patients keep their free flap alive after reconstructive surgery. A "free flap" is a piece of tissue that is moved from one part of the body to another to help with healing and appearance. The main goal of this study is to see which treatment leads to better survival rates for the free flap after surgery.

To participate, you must be between 18 and 70 years old and scheduled for free flap surgery. However, if you have certain medical conditions, like a known allergy to heparin or aspirin, a history of bleeding problems, or if you're taking other blood-thinning medications, you won't be eligible. If you join the trial, you'll be randomly assigned to receive either heparin or the heparin-aspirin combination and will be monitored to see how well the free flap survives over time. It’s important to know that this trial is not yet recruiting participants, so it may take some time before it begins. Your involvement could help doctors learn more about the best ways to support healing in these types of surgeries.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients undergoing free flap surgery
• • Age between 18 and 70 years
• Exclusion Criteria:
• • Known hypersensitivity to heparin or aspirin
• • History of bleeding disorders
• • Concurrent use of other anticoagulant or antiplatelet medications
• • Severe renal or hepatic impairment
• • Preoperative use of aspirin that could not be stopped five days before surgery due to a higher risk of cardiac-related complications.